You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. The Effects of an Oral Nitric Oxide Lozenge on Peripheral Artery Disease

    SBC: Neogenis Laboratories, Inc.            Topic: 213

    Abstract Peripheral artery disease PAD is a common circulatory problem in which narrowed arteries reduce blood flow to your limbs thereby restricting blood flow During exercise or simply walking there is not sufficient blood flow to keep up with the metabolic demand This causes symptoms most notably leg pain when walking intermittent claudication PAD is also likely to be a sign of more w ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Enhancing Care of the Aged and Dying in Prisons

    SBC: KLEIN BUENDEL, INC            Topic: NIA

    The United States has the highest rate of incarceration in the world There are over state and federal prisons housing over million prisoners in the United States The demographics of the prison population are shifting Longer sentences and constrained options for early release compound this trend The older adult segment of prison populations has more than tripled since The health ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Polymeric Percutaneous Pulmonary Valve for Use in Young Children

    SBC: Polyvascular Corp            Topic: NHLBI

    DESCRIPTION provided by applicant Congenital heart defects CHD represent the most common type of birth defect and are a leading cause of childhood deaths in the developed world Many forms of CHD require pulmonary valve PV replacement surgery which is typically performed with biologic valves such as human cadaveric donor valves which are in short supply Additionally such biologically ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. A small molecule integrin activator to enhance cord blood transplant

    SBC: 7 Hills Pharma LLC            Topic: NHLBI

    DESCRIPTION provided by applicant This proposal is in response to PA the parent announcement for STTR R grant applications Hematopoietic stem cell transplantation has become a preferred treatment for hematological malignancies and certain genetic disorders The use of umbilical cord blood cells as a source of hematopoietic stem cells for bone marrow transplantation has increased st ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Preclinical Evaluation of NCS-382 in Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)

    SBC: SPERAGEN, INC.            Topic: 107

    SUMMARY Succinic semialdehyde dehydrogenase deficiency SSHDHD is an autosomal recessively inherited ultra rare disorder caused by accumulation of two neuromodulators in tissues and biofluids hydroxybutyrate GHB and aminobutyric acid GABA It is believed that the toxic action of GABA and GHB is mediated by their action on specific receptors widely distributed in the brain and other organ ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Macromolecule Crystallization Screening Results Analysis

    SBC: iXpressGenes, Inc.            Topic: 100

    Project Summary Crystallization followed by subsequent structure determination is a major step in understanding the structure function relationship of macromolecules Understanding macromolecule structure has become a key part in the development of new pharmaceuticals and is a major area of NIH research Crystallization however is also the rate limiting step despite technological efforts to a ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. STAT Inhibitors for Asthma Therapy

    SBC: Atrapos Therapeutics, LLC            Topic: NIAID

    Asthma a chronic disease of the lungs that affects adults and children of all ages has markedly increased in incidence prevalence and severity over the past several decades with a prevalence of in the U S The current standard of care for asthma consists of the combination of long acting beta adrenergic receptor agonists which relieve airway constriction and glucocorticosteroids which ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    SBC: 7 Hills Pharma LLC            Topic: 102

    DESCRIPTION provided by applicant Recent FDA approvals of ipilimumab nivolumab and pembrolizumab which target checkpoint receptors cytotoxic T lymphocyte associated antigen CTLA and programmed death PD have ushered in a new era of cancer immunotherapy in metastatic melanoma Despite unprecedented overall survival benefits with combination therapy the incidence of complete respo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government